Interleukin 2 subcutaneous injection

DRUG2 trials

Sponsors

Second Affiliated Hospital of Soochow University, Qingdao Sino-Cell Biomedicine Co., Ltd.

Conditions

Advanced Solid TumorClear Cell Renal Cell CarcinomaRefractory Tumor

Phase 1

Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer

Not yet recruitingNCT07770802

Qingdao Sino-Cell Biomedicine Co., Ltd.Clear Cell Renal Cell Carcinoma

Start: 2026-10-01End: 2027-08-01Target: 15Updated: 2026-08-18

Phase 2

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Second Affiliated Hospital of Soochow UniversityAdvanced Solid Tumor, Refractory Tumor

Start: 2023-06-16End: 2024-12-31Target: 30Updated: 2023-09-21

Related Papers

Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study)

Technology in Cancer Research & Treatment2025-06-01